December 7, 2020
Immunicum’s ilixadencel for tumors get’s FDA’s fast track
Immunicum AB has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Immunicium
February 11, 2019
Immunicium to treat cancer patients with its lead in-development-product, ILIAD
Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.